205 related articles for article (PubMed ID: 20623938)
41. The management of pain in spasticity.
Ward AB; Kadies M
Disabil Rehabil; 2002 May; 24(8):443-53. PubMed ID: 12033999
[TBL] [Abstract][Full Text] [Related]
42. [Treatment of the spastic drop foot with botulinum toxin type A in adult patients].
Voller B; Földy D; Hefter H; Auff E; Schnider P
Wien Klin Wochenschr; 2001; 113 Suppl 4():25-9. PubMed ID: 15506049
[TBL] [Abstract][Full Text] [Related]
43. Hallucinations after abrupt withdrawal of oral and intrathecal baclofen.
D'Aleo G; Cammaroto S; Rifici C; Marra G; Sessa E; Bramanti P; Di Bella P
Funct Neurol; 2007; 22(2):81-8. PubMed ID: 17637210
[TBL] [Abstract][Full Text] [Related]
44. [Efficacy of intrathecal baclofen in the treatment of spasticity in stroke].
Lamotte D; Cantalloube S
Ann Readapt Med Phys; 2007 Apr; 50(3):165-9. PubMed ID: 17145092
[TBL] [Abstract][Full Text] [Related]
45. [From physical therapy to botulinum toxin: treatments in distressing spasticity].
Bischoff A
MMW Fortschr Med; 2011 Mar; 153(9):16. PubMed ID: 21638856
[No Abstract] [Full Text] [Related]
46. Management of pediatric spasticity.
Melnick ME; Shellenberger MK
Compr Ther; 1982 Oct; 8(10):20-6. PubMed ID: 7140200
[No Abstract] [Full Text] [Related]
47. Management of childhood spasticity: a neurosurgical perspective.
Mandigo CE; Anderson RC
Pediatr Ann; 2006 May; 35(5):354-62. PubMed ID: 16722294
[TBL] [Abstract][Full Text] [Related]
48. Management of spasticity.
Ko CK; Ward AB
Br J Hosp Med; 1997 Oct 15-Nov 4; 58(8):400-5. PubMed ID: 9509042
[TBL] [Abstract][Full Text] [Related]
49. [Current data on bipolar disorders, epilepsy and spasticity. 4. Neuro-Forum, Dresden].
Fortschr Neurol Psychiatr; 1999 May; 67(5 Suppl Aktuelles):1-12. PubMed ID: 10368778
[No Abstract] [Full Text] [Related]
50. Medical treatment of spasticity.
Delaney JF
Curr Probl Surg; 1980 Apr; 17(4):245-8. PubMed ID: 6892798
[No Abstract] [Full Text] [Related]
51. [Spasticity: therapy of increased reflexes or movement disorder?].
Dietz V
Nervenarzt; 1990 Oct; 61(10):581-6. PubMed ID: 2274090
[No Abstract] [Full Text] [Related]
52. Efficacy and safety of tizanidine in the treatment of spasticity in patients with spinal cord injury. North American Tizanidine Study Group.
Nance PW; Bugaresti J; Shellenberger K; Sheremata W; Martinez-Arizala A
Neurology; 1994 Nov; 44(11 Suppl 9):S44-51; discussion S51-2. PubMed ID: 7970010
[TBL] [Abstract][Full Text] [Related]
53. Multi-centre, double-blind trial of a novel antispastic agent, tizanidine, in spasticity associated with multiple sclerosis.
Eyssette M; Rohmer F; Serratrice G; Warter JM; Boisson D
Curr Med Res Opin; 1988; 10(10):699-708. PubMed ID: 3286128
[TBL] [Abstract][Full Text] [Related]
54. Experience with external pump trial prior to implantation for intrathecal baclofen in ambulatory patients with spastic cerebral palsy.
Bleyenheuft C; Filipetti P; Caldas C; Lejeune T
Neurophysiol Clin; 2007; 37(1):23-8. PubMed ID: 17418354
[TBL] [Abstract][Full Text] [Related]
55. [Safety and tolerance of single-dose botulinum toxin Type A treatment in 204 patients with spasticity and localized associated symptoms. Austrian and German botulinum toxin A spasticity study group].
Wissel J; Müller J; Heinen F; Mall V; Sojer M; Ebersbach G; Poewe W
Wien Klin Wochenschr; 1999 Oct; 111(20):837-42. PubMed ID: 10586488
[TBL] [Abstract][Full Text] [Related]
56. A randomized, double-blind, placebo-controlled study of the efficacy and safety of tolperisone in spasticity following cerebral stroke.
Stamenova P; Koytchev R; Kuhn K; Hansen C; Horvath F; Ramm S; Pongratz D
Eur J Neurol; 2005 Jun; 12(6):453-61. PubMed ID: 15885050
[TBL] [Abstract][Full Text] [Related]
57. [Tolperisone in spasticity and muscle spasm. Tolperisone in multiple sclerosis].
Nervenarzt; 1996 Jul; 67(7 Suppl Tolperison):1-4. PubMed ID: 9404528
[No Abstract] [Full Text] [Related]
58. Management of spasticity, pain, and paroxysmal phenomena in multiple sclerosis.
Schapiro RT
Curr Neurol Neurosci Rep; 2001 May; 1(3):299-302. PubMed ID: 11898533
[TBL] [Abstract][Full Text] [Related]
59. A multi-centre, double-blind trial of tizanidine, a new antispastic agent, in spasticity associated with hemiplegia.
Bes A; Eyssette M; Pierrot-Deseilligny E; Rohmer F; Warter JM
Curr Med Res Opin; 1988; 10(10):709-18. PubMed ID: 3286129
[TBL] [Abstract][Full Text] [Related]
60. Spasticity in children and young people with non-progressive brain disorders: summary of NICE guidance.
Mugglestone MA; Eunson P; Murphy MS;
BMJ; 2012 Jul; 345():e4845. PubMed ID: 22836108
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
